The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

With thousands of press releases published each week, it can be difficult to keep up with everything on . To help journalists ...

A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans at risk for kidney failure.

Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR ...

Iron deficiency may be linked to non-dialysis-dependent chronic kidney disease and mortality in patients without anemia, according to results of a nationwide cohort study.While iron is a key component ...

Chronic kidney disease (CKD) is a growing global health concern, significantly contributing to morbidity and mortality rates worldwide. Characterized by a ...

With thousands of press releases published each week, it can be difficult to keep up with everything on . To help healthcare ...

ProKidney’s Rilparencel shows promise for CKD patients, with Phase 2 data expected in 2025. Learn why PROK stock is a “Buy” ...